In the Casselholm study, EYLEA® significantly reduced treatment burden vs. ranibizumab while improving vision1
EYLEA (n=22) significantly reduced injection frequency by 24% vs. ranibizumab (n=23) in a treat-and-extend (T&E) regimen1
- 67% of the whole cohort of patients (n=43) achieved a visual gain of ≥15 letters1
- The majority of EYLEA-treated patients had a 12-week injection interval while the majority of ranibizumab patients needed follow-up with an interval of 6 weeks or longer1
The present study shows that in patients with ME secondary to CRVO, the use of aflibercept significantly reduces injection frequency compared with ranibizumab in a treat-and extend regimen. Thus, treatment burden can be reduced without negative impact on visual outcome.
BCVA, best-corrected visual acuity; CI, confidence interval; ETDRS, Early Treatment Diabetic Retinopathy Study; ITT, intention-to-treat; PRN, pro re nata; T&E, treat-and-extend; ME, Macular Edema.
- Casselholm de Salles M, Amrén U, Kvanta A, et al. Injection frequency of aflibercept versus ranibizumab in a treat-and-extend regimen for central retinal vein occlusion. Retina. 2018;0:1-7.